Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !
Melexis Zukünftiges Wachstum
Future Kriterienprüfungen 3/6
Melexis wird ein jährliches Gewinn- und Umsatzwachstum von 7% bzw. 7.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 34.6% betragen.
Wichtige Informationen
7.0%
Wachstumsrate der Gewinne
7.0%
EPS-Wachstumsrate
Semiconductor Gewinnwachstum | 19.1% |
Wachstumsrate der Einnahmen | 7.5% |
Zukünftige Eigenkapitalrendite | 34.6% |
Analystenabdeckung | Good |
Zuletzt aktualisiert | 06 Jun 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Melexis (EBR:MELE) Knows How To Allocate Capital
Jun 07Melexis (EBR:MELE) Seems To Use Debt Quite Sensibly
May 22Shareholders Will Probably Be Cautious Of Increasing Melexis NV's (EBR:MELE) CEO Compensation At The Moment
May 08Calculating The Fair Value Of Melexis NV (EBR:MELE)
Mar 27At €78.60, Is Melexis NV (EBR:MELE) Worth Looking At Closely?
Mar 14Many Would Be Envious Of Melexis' (EBR:MELE) Excellent Returns On Capital
Feb 28Melexis' (EBR:MELE) Solid Earnings May Rest On Weak Foundations
Feb 15Melexis (EBR:MELE) Has A Pretty Healthy Balance Sheet
Jan 02What Does Melexis NV's (EBR:MELE) Share Price Indicate?
Dec 09Here's Why Melexis (EBR:MELE) Has Caught The Eye Of Investors
Nov 27Melexis (EBR:MELE) Knows How To Allocate Capital
Nov 15Calculating The Intrinsic Value Of Melexis NV (EBR:MELE)
Nov 03Melexis' (EBR:MELE) Dividend Will Be €0.91
Oct 10Melexis (EBR:MELE) Is Due To Pay A Dividend Of €0.91
Sep 26Does Melexis (EBR:MELE) Have A Healthy Balance Sheet?
Sep 17Melexis (EBR:MELE) Has Announced A Dividend Of €0.91
Sep 02Melexis (EBR:MELE) Has Announced A Dividend Of €0.91
Aug 19Melexis' (EBR:MELE) Dividend Will Be €0.91
Aug 05Melexis (EBR:MELE) Might Become A Compounding Machine
Jul 13Do Melexis' (EBR:MELE) Earnings Warrant Your Attention?
Jun 29Estimating The Intrinsic Value Of Melexis NV (EBR:MELE)
Jun 02At €99.75, Is Melexis NV (EBR:MELE) Worth Looking At Closely?
Apr 11With EPS Growth And More, Melexis (EBR:MELE) Makes An Interesting Case
Mar 27Is It Time To Consider Buying Melexis NV (EBR:MELE)?
Jan 09Here's Why Melexis (EBR:MELE) Has Caught The Eye Of Investors
Dec 24Is Melexis NV (EBR:MELE) Expensive For A Reason? A Look At Its Intrinsic Value
Nov 24Melexis (EBR:MELE) Is Paying Out A Dividend Of €0.91
Oct 18Melexis' (EBR:MELE) Dividend Will Be €0.91
Oct 04Melexis' (EBR:MELE) Dividend Will Be €0.91
Sep 20We Ran A Stock Scan For Earnings Growth And Melexis (EBR:MELE) Passed With Ease
Sep 19Melexis' (EBR:MELE) Dividend Will Be €0.91
Sep 05Melexis (EBR:MELE) Is Due To Pay A Dividend Of €0.91
Aug 22Melexis (EBR:MELE) Will Pay A Dividend Of €0.91
Aug 04Is There An Opportunity With Melexis NV's (EBR:MELE) 31% Undervaluation?
Jul 11Melexis (EBR:MELE) Looks To Prolong Its Impressive Returns
Jun 27Does Melexis (EBR:MELE) Deserve A Spot On Your Watchlist?
Jun 13Should You Think About Buying Melexis NV (EBR:MELE) Now?
Mar 01Calculating The Fair Value Of Melexis NV (EBR:MELE)
Feb 14Melexis (EBR:MELE) Looks To Prolong Its Impressive Returns
Dec 06Should You Think About Buying Melexis NV (EBR:MELE) Now?
Nov 18Is Melexis NV (EBR:MELE) Expensive For A Reason? A Look At Its Intrinsic Value
Sep 29Does Melexis (EBR:MELE) Have A Healthy Balance Sheet?
Sep 15Melexis (EBR:MELE) Will Be Hoping To Turn Its Returns On Capital Around
Jul 18Is It Time To Consider Buying Melexis NV (EBR:MELE)?
Jun 21These 4 Measures Indicate That Melexis (EBR:MELE) Is Using Debt Safely
Jun 08Melexis NV's (EBR:MELE) Intrinsic Value Is Potentially 20% Below Its Share Price
Apr 11What Is The Ownership Structure Like For Melexis NV (EBR:MELE)?
Mar 17Is Melexis (EBR:MELE) Likely To Turn Things Around?
Feb 28Does Melexis (EBR:MELE) Have A Healthy Balance Sheet?
Feb 15Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
12/31/2026 | 1,182 | 256 | 227 | 282 | 11 |
12/31/2025 | 1,080 | 227 | 207 | 269 | 11 |
12/31/2024 | 999 | 206 | 163 | 237 | 11 |
3/31/2024 | 978 | 211 | -91 | 3 | N/A |
12/31/2023 | 964 | 209 | -92 | 3 | N/A |
9/30/2023 | 938 | 212 | -74 | 7 | N/A |
6/30/2023 | 909 | 204 | -21 | 42 | N/A |
3/31/2023 | 881 | 199 | 132 | 184 | N/A |
12/31/2022 | 836 | 197 | 148 | 188 | N/A |
9/30/2022 | 779 | 178 | 158 | 194 | N/A |
6/30/2022 | 722 | 166 | 124 | 161 | N/A |
3/31/2022 | 672 | 152 | 105 | 140 | N/A |
12/31/2021 | 644 | 131 | 103 | 142 | N/A |
9/30/2021 | 625 | 122 | 95 | 132 | N/A |
6/30/2021 | 584 | 100 | 92 | 123 | N/A |
3/31/2021 | 525 | 76 | 80 | 109 | N/A |
12/31/2020 | 508 | 69 | 71 | 96 | N/A |
9/30/2020 | 487 | 61 | 72 | 95 | N/A |
6/30/2020 | 489 | 61 | 81 | 104 | N/A |
3/31/2020 | 509 | 67 | 75 | 101 | N/A |
12/31/2019 | 487 | 60 | 68 | 94 | N/A |
9/30/2019 | 501 | 73 | 67 | 105 | N/A |
6/30/2019 | 525 | 88 | 45 | 96 | N/A |
3/31/2019 | 547 | 101 | 35 | 98 | N/A |
12/31/2018 | 569 | 115 | 23 | 100 | N/A |
9/30/2018 | 560 | 114 | 5 | 78 | N/A |
6/30/2018 | 541 | 112 | 22 | 89 | N/A |
3/31/2018 | 527 | 114 | 45 | 106 | N/A |
12/31/2017 | 512 | 111 | N/A | 113 | N/A |
9/30/2017 | 499 | 109 | N/A | 116 | N/A |
6/30/2017 | 486 | 107 | N/A | 96 | N/A |
3/31/2017 | 470 | 99 | N/A | 108 | N/A |
12/31/2016 | 456 | 96 | N/A | 108 | N/A |
9/30/2016 | 439 | 93 | N/A | 116 | N/A |
6/30/2016 | 426 | 93 | N/A | 134 | N/A |
3/31/2016 | 415 | 95 | N/A | 127 | N/A |
12/31/2015 | 400 | 99 | N/A | 115 | N/A |
9/30/2015 | 386 | 97 | N/A | 109 | N/A |
6/30/2015 | 371 | 97 | N/A | 103 | N/A |
3/31/2015 | 351 | 93 | N/A | 97 | N/A |
12/31/2014 | 332 | 85 | N/A | 95 | N/A |
9/30/2014 | 319 | 81 | N/A | 95 | N/A |
6/30/2014 | 304 | 71 | N/A | 84 | N/A |
3/31/2014 | 289 | 63 | N/A | 80 | N/A |
12/31/2013 | 275 | 55 | N/A | 71 | N/A |
9/30/2013 | 262 | 56 | N/A | 57 | N/A |
6/30/2013 | 255 | 53 | N/A | 56 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: MELEDas prognostizierte Gewinnwachstum (7% pro Jahr) liegt über der Sparquote (1.1%).
Ertrag vs. Markt: MELEDie Erträge des Unternehmens (7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Belgian (16.9% pro Jahr).
Hohe Wachstumserträge: MELEDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: MELEDie Einnahmen des Unternehmens (7.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Belgian (6.1% pro Jahr).
Hohe Wachstumseinnahmen: MELEDie Einnahmen des Unternehmens (7.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: MELEDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (34.6%)